Shire Delivers A Strong First Quarter Performance

April 28, 2011

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to March 31, 2011.

Financial Highlights Q1 2011(1)
Product sales $889 million +24%
Total revenues $972 million +19%
   
Non GAAP operating income $306 million +15%
US GAAP operating income $267 million +22%
   
Non GAAP diluted earnings per ADS $1.23 +22%
US GAAP diluted earnings per ADS $1.11 +25%
   
Non GAAP cash generation $208 million -25%
Non GAAP free cash flow $155 million +9%
US GAAP net cash provided by operating activities $202 million +8%

(1) Percentages compare to equivalent 2010 period.

The Non GAAP financial measures included within this release are explained on page 20 of the full release, and are reconciled to the most directly comparable financial measures prepared in accordance with US GAAP on pages 17 - 19 of the full release.

Angus Russell, Chief Executive Officer, commented:

"Shire delivered a strong first quarter with product sales from our diverse portfolio up 24%. Non GAAP diluted earnings per ADS increased 22% in the quarter. Sales of our ADHD treatments INTUNIV, VYVANSE and ADDERALL XR were all up and the overall ADHD market in the US showed good growth (13%). GI sales performed well in the first quarter, driven by LIALDA.

Our rare disease treatments, particularly VPRIV and REPLAGAL, continued their success around the world with strong growth and represent 30% of our total product sales.

This quarter we were granted FDA approval of INTUNIV as adjunctive therapy to stimulants for ADHD, we filed our US complete response for FIRAZYR and were granted European approval for FIRAZYR self-administration. Our new HGT manufacturing site in Massachusetts is progressing as planned and we’ve now filed for European approval of REPLAGAL in this facility.

The successful advancement of our pipeline is driving increased investment in research and development. Early data from exploratory clinical trials for VYVANSE in potential new uses is very encouraging, including the most recent findings in negative symptoms of schizophrenia, announced today. We have further plans for a study in binge eating disorder as well as the progression of our phase 3 program in major depressive disorder. Our Carrier Wave Guanfacine program continues to make progress. We anticipate further pipeline news this year.

We have made a strong start to 2011, which underpins our previously stated financial guidance."